LARGER VIALS = LARGER SAVINGS PER mg

SLU-PP-332

SLU-PP-332

$80.00
$80.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

SLU-PP-332

SLU-PP-332

$80.00
$80.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

SLU-PP-332 is an experimental small-molecule agonist of the estrogen-related receptor (ERR) family. It has been investigated for its ability to enhance mitochondrial biogenesis, increase energy expenditure, and improve metabolic function, with potential applications in obesity and metabolic disease research.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

SLU-PP-332 is a novel small-molecule PPARδ (peroxisome proliferator-activated receptor delta) agonist developed for research into metabolic regulation, exercise mimetics, and energy homeostasis. Unlike peptides, SLU-PP-332 is a non-peptidic compound designed to activate transcriptional programs involved in fatty acid oxidation, mitochondrial biogenesis, and endurance metabolism. It has been studied as part of a new class of exercise-mimicking drugs with potential applications in obesity, type 2 diabetes, and performance research.

Structure

  • Type: Synthetic small-molecule PPARδ agonist
  • Target: Nuclear receptor PPARδ
  • Mechanism:



    Binds and activates PPARδ transcription factor



    Upregulates genes for fatty acid transport and oxidation



    Enhances mitochondrial function, endurance capacity, and energy expenditure

Research

Exercise Mimetic Effects

  • Mimics molecular changes induced by endurance training.
  • Increases oxidative muscle fibers and mitochondrial capacity.
  • Enhances running endurance in preclinical models.

Metabolic Regulation

  • Improves lipid utilization and reduces fat accumulation.
  • Shown to lower plasma triglycerides and cholesterol in animal studies.
  • Increases insulin sensitivity and glucose tolerance.

Obesity & Diabetes Research

  • Promotes weight loss in high-fat diet animal models.
  • Prevents diet-induced metabolic dysfunction via fat oxidation.

Muscle & Performance

  • Converts muscle phenotype toward fatigue-resistant oxidative fibers.
  • May synergize with AMPK activation (similar to AICAR studies).

Safety Profile

  • Still preclinical; long-term safety unknown.
  • Potential risks include cardiac hypertrophy or tumorigenesis (seen with some PPAR agonists in past studies).

Summary

SLU-PP-332 is a PPARδ agonist studied as a potential exercise mimetic and metabolic regulator. Research highlights include:

  • Enhances endurance capacity and oxidative metabolism
  • Improves lipid and glucose metabolism
  • Investigated in obesity, diabetes, and performance optimization
  • Preclinical safety and efficacy remain under investigation

This compound is supplied as a lyophilized powder. Store at 2–8 °C, protected from light and moisture. For long-term storage, keep unopened vials at −20 °C. After reconstitution, prepare under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Narkar VA, et al. AMPK and PPARδ agonists mimic exercise by altering muscle metabolism. *Cell*. 2008;134(3):405–415. doi:10.1016/j.cell.2008.06.051

2. Fan W, et al. PPARδ promotes oxidative muscle fiber specification and endurance. *Proc Natl Acad Sci U S A*. 2017;114(36):E7419–E7428. doi:10.1073/pnas.1706895114

3. Schuler M, et al. PPARδ as a nuclear receptor regulator of metabolism and exercise adaptation. *J Biol Chem*. 2006;281(31):21266–21274. doi:10.1074/jbc.M602394200

4. Wang YX, et al. Regulation of muscle fiber type and metabolism by PPARδ. *PLoS Biol*. 2004;2(10):e294. doi:10.1371/journal.pbio.0020294

5. Dressel U, et al. PPARδ agonism improves glucose metabolism in skeletal muscle. *Endocrinology*. 2003;144(3): 1143–1153. doi:10.1210/en.2002-220732

6. Oliver WR, et al. A selective PPARδ agonist promotes reverse cholesterol transport. *Proc Natl Acad Sci U S A*. 2001;98(9):5306–5311. doi:10.1073/pnas.091021198

7. Luquet S, et al. PPARδ controls muscle oxidative capacity and endurance. *FASEB J*. 2003;17(15):2299–2301. doi:10.1096/fj.03-0388fje

8. Xu HE, et al. Structural basis for ligand activation of PPARδ. *Mol Cell*. 2002;10(3):687–698. doi:10.1016/S1097-2765(02)00650-0

9. Krämer DK, et al. PPARδ activation enhances skeletal muscle fatty acid oxidation and endurance. *Am J Physiol Endocrinol Metab*. 2005;288(6):E1259–E1267. doi:10.1152/ajpendo.00475.2004

10. Tanaka T, et al. Therapeutic implications of PPARδ agonists in obesity and metabolic syndrome. *Pharmacol Ther*. 2003;100(2):159–173. doi:10.1016/j.pharmthera.2003.08.002